Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
August 7, 2017 4:01 PM EDTWebcast and Conference Call today at 4:30 p.m. ET
Cash and marketable securities totaled $235.3 million at June 30, 2017 Royalty revenue for the quarter was $7.5 million Milestone payments totaling $65 million earned following AbbVies EU approval of MAVIRET (glecaprevir/pibrentasvir) in July, and U.S. approval of MAVYRET (glecaprevir/pibrentasvir) in August RSV and NASH/PBC clinical programs continue to advance toward new stages next quarterWATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta... More
